AR106960A2 - SALES Y POLIMORFOS FARMACÉUTICOS DE UN INHIBIDOR DEL FACTOR Xa - Google Patents

SALES Y POLIMORFOS FARMACÉUTICOS DE UN INHIBIDOR DEL FACTOR Xa

Info

Publication number
AR106960A2
AR106960A2 ARP160103799A ARP160103799A AR106960A2 AR 106960 A2 AR106960 A2 AR 106960A2 AR P160103799 A ARP160103799 A AR P160103799A AR P160103799 A ARP160103799 A AR P160103799A AR 106960 A2 AR106960 A2 AR 106960A2
Authority
AR
Argentina
Prior art keywords
salt
salts
clause
compound
polymorphes
Prior art date
Application number
ARP160103799A
Other languages
English (en)
Inventor
Langlands Graeme
P Kanter James
Grant Craig
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR106960A2 publication Critical patent/AR106960A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Sales que comprenden un compuesto y un ácido que tiene actividad contra el Factor Xa de mamíferos. También se proveen métodos para elaborar dicho compuesto. Reivindicación 1: Una sal, caracterizada porque comprende un compuesto de fórmula (1) y un ácido seleccionado a partir del grupo que consiste en clorhídrico, láctico, maleico, fenoxiacético, propiónico, succínico, adípico, ascórbico, alcanfórico, glucónico, fosfórico, tártrico, cítrico, metansulfónico, fumárico, glicólico, naftaleno-1,5-disulfónico, gentísico y benceno sulfónico. Reivindicación 6: La sal de la cláusula 4, caracterizada porque la sal está representada por medio de la fórmula (2). Reivindicación 8: La sal de la cláusula 7, caracterizada porque tiene un patrón de difracción de rayos X en polvo que tiene al menos cuatro localizaciones de picos característicos aproximados que se seleccionan de 4,9; 9,7; 13,8; 14,1; 15,2; 17,6; 18,5; 20,8; 21,6; 22,7; 24,1; 26,3; 26,8 grados 2q. Reivindicación 9: La sal de la cláusula 7, caracterizada porque tiene un patrón de difracción de rayos X en polvo que tiene al menos ocho localizaciones de picos característicos aproximados que se seleccionan de 4,9; 9,7; 11,8; 13,8; 14,1; 15,2; 17,6; 18,5; 19,9; 20,8; 21,6; 22,7; 24,1; 25,0; 26,3; 26,8 grados 2q.
ARP160103799A 2005-11-08 2016-12-12 SALES Y POLIMORFOS FARMACÉUTICOS DE UN INHIBIDOR DEL FACTOR Xa AR106960A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73522405P 2005-11-08 2005-11-08

Publications (1)

Publication Number Publication Date
AR106960A2 true AR106960A2 (es) 2018-03-07

Family

ID=38023988

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060104900A AR056787A1 (es) 2005-11-08 2006-11-08 Sales y polimorfos farmaceuticos de un inhibidor del factor xa
ARP160103799A AR106960A2 (es) 2005-11-08 2016-12-12 SALES Y POLIMORFOS FARMACÉUTICOS DE UN INHIBIDOR DEL FACTOR Xa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP060104900A AR056787A1 (es) 2005-11-08 2006-11-08 Sales y polimorfos farmaceuticos de un inhibidor del factor xa

Country Status (20)

Country Link
US (7) US7598276B2 (es)
EP (2) EP2431358A1 (es)
JP (2) JP5227178B2 (es)
KR (1) KR101358574B1 (es)
CN (2) CN101304971B (es)
AR (2) AR056787A1 (es)
AT (1) ATE549317T1 (es)
AU (1) AU2006311544B2 (es)
BR (1) BRPI0618362A2 (es)
CA (1) CA2627086C (es)
DK (1) DK1948608T3 (es)
ES (1) ES2384116T3 (es)
IL (2) IL190524A (es)
NZ (2) NZ592533A (es)
PE (2) PE20110070A1 (es)
PT (1) PT1948608E (es)
RU (1) RU2440986C2 (es)
TW (1) TWI443088B (es)
WO (1) WO2007056517A2 (es)
ZA (1) ZA200803820B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
JP5020073B2 (ja) 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク． 第Ｘａ因子阻害剤
US7598276B2 (en) * 2005-11-08 2009-10-06 Millenium Pharmaceuticals, Inc. Pharmaceutical salts and polymorphs of a factor Xa inhibitor
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
TW200813017A (en) 2006-05-05 2008-03-16 Millennium Pharm Inc Factor XA inhibitors
ES2382055T3 (es) * 2006-11-02 2012-06-04 Millennium Pharmaceuticals, Inc. Métodos para sintetizar sales farmacéuticas de un inhibidor del factor Xa
CA2671502C (en) 2006-12-08 2017-01-24 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
WO2008086226A2 (en) * 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
WO2008127682A2 (en) * 2007-04-13 2008-10-23 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
JP5439363B2 (ja) * 2007-05-02 2014-03-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 血小板ａｄｐ受容体阻害剤として作用する化合物による併用療法
PT2193196T (pt) 2007-09-28 2016-10-24 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
CN102316893B (zh) 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
DK3604510T3 (da) 2009-03-30 2025-06-30 Alexion Pharma Inc Antidoter til faktor-Xa-hæmmere og fremgangsmåder til anvendelse deraf
CN102625712B (zh) 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法
EP2513094B1 (en) * 2009-12-17 2015-12-16 Millennium Pharmaceuticals, Inc. Crystalline salts of a factor xa inhibitor
US8742120B2 (en) * 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
JP5766204B2 (ja) 2009-12-17 2015-08-19 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の合成方法
EA015918B1 (ru) * 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
TW201240664A (en) 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
WO2013033370A1 (en) * 2011-08-31 2013-03-07 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104341343B (zh) * 2013-07-24 2018-09-28 四川海思科制药有限公司 贝曲西班的晶型及其制备方法和用途
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
JP6742986B2 (ja) 2014-08-20 2020-08-19 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子解毒剤の凍結乾燥製剤
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN106995405A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种贝曲西班马来酸盐无定型物及其制备方法
US20190046450A1 (en) 2016-02-24 2019-02-14 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
WO2017208169A1 (en) * 2016-06-02 2017-12-07 Dr. Reddy’S Laboratories Limited Polymorphs of betrixaban & its maleate salt
EP3254674A1 (en) 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
HUE054597T2 (hu) 2016-06-17 2021-09-28 Alexion Pharma Inc Az XA faktor származékainak elõkészítése
WO2018042320A1 (en) * 2016-08-30 2018-03-08 Dr. Reddy’S Laboratories Limited Salts of betrixaban and processes for preparation thereof
EP3293174A1 (en) 2016-09-09 2018-03-14 Sandoz Ag Crystalline salts of betrixaban
WO2018069936A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof
CN108017576B (zh) * 2016-11-01 2022-06-21 石药集团中奇制药技术（石家庄）有限公司 一种贝曲西班及其盐酸盐的制备方法，以及它们的晶型
CN108586325A (zh) * 2017-03-16 2018-09-28 上海度德医药科技有限公司 一种Betrixaban中间体的制备方法
WO2018229796A2 (en) 2017-06-14 2018-12-20 Mylan Laboratories Limited A process for betrixaban hydrochloride and betrixaban maleate salt
CN107868039A (zh) * 2017-11-27 2018-04-03 中国药科大学 一种贝曲沙班中间体n－（5－氯－2－吡啶基）－2－［（4－氰基苯甲酰基）氨基］－5－甲氧基苯甲酰胺的制备方法
WO2022211680A1 (ru) * 2021-03-30 2022-10-06 Общество С Ограниченной Ответственностью "Фармадиол" Способ получения антикоагулянта n-(5-хлорпиридин-2-ил)-2-({4-[этан-имидоил(метил)амино]бензоил}амино)-5-метилбензамид гидрохлорида
CN115057854A (zh) * 2022-04-19 2022-09-16 河北常山生化药业股份有限公司 马来酸阿伐曲泊帕中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504769A (ja) 1992-12-15 1996-05-21 コルバス・インターナショナル、インコーポレイテッド 因子Ｘａの新規インヒビター
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
TW300888B (es) 1994-12-02 1997-03-21 Yamanouchi Pharma Co Ltd
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
KR20000062284A (ko) 1996-12-23 2000-10-25 블레어 큐. 퍼거슨 인자 Ｘａ 억제제로서의 질소 함유 헤테로방향족 화합물
AU8747598A (en) 1997-08-27 1999-03-16 Kissei Pharmaceutical Co. Ltd. 3-amidinoaniline derivatives, activated blood coagulation factor x inhibitors, and intermediates for producing both
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
HU230773B1 (hu) * 1999-09-17 2018-03-28 Millennium Pharmaceuticals, Inc. Benzamidok és rokon Xa faktor inhibitorok
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7598276B2 (en) 2005-11-08 2009-10-06 Millenium Pharmaceuticals, Inc. Pharmaceutical salts and polymorphs of a factor Xa inhibitor
ES2382055T3 (es) 2006-11-02 2012-06-04 Millennium Pharmaceuticals, Inc. Métodos para sintetizar sales farmacéuticas de un inhibidor del factor Xa

Also Published As

Publication number Publication date
CN102336702A (zh) 2012-02-01
US20130064806A1 (en) 2013-03-14
US20160101089A1 (en) 2016-04-14
RU2008123055A (ru) 2009-12-20
EP1948608A2 (en) 2008-07-30
TWI443088B (zh) 2014-07-01
HK1115131A1 (en) 2008-11-21
JP2009514976A (ja) 2009-04-09
US9061019B2 (en) 2015-06-23
NZ567992A (en) 2011-05-27
US8557852B2 (en) 2013-10-15
JP5227178B2 (ja) 2013-07-03
TW200736221A (en) 2007-10-01
PE20110070A1 (es) 2011-03-04
PT1948608E (pt) 2012-05-24
IL213487A0 (en) 2011-07-31
US20190046510A1 (en) 2019-02-14
EP2431358A1 (en) 2012-03-21
KR101358574B1 (ko) 2014-02-04
WO2007056517A2 (en) 2007-05-18
AU2006311544A1 (en) 2007-05-18
CA2627086C (en) 2016-04-05
BRPI0618362A2 (pt) 2011-08-30
US7598276B2 (en) 2009-10-06
AU2006311544B2 (en) 2012-03-08
IL190524A0 (en) 2008-12-29
US20100063113A1 (en) 2010-03-11
CA2627086A1 (en) 2007-05-18
PE20070717A1 (es) 2007-08-17
CN101304971A (zh) 2008-11-12
KR20080065662A (ko) 2008-07-14
US9555023B2 (en) 2017-01-31
CN101304971B (zh) 2011-09-07
US20070112039A1 (en) 2007-05-17
US20170326119A1 (en) 2017-11-16
DK1948608T3 (da) 2012-07-02
CN102336702B (zh) 2015-02-11
AR056787A1 (es) 2007-10-24
IL190524A (en) 2013-02-28
EP1948608B1 (en) 2012-03-14
ZA200803820B (en) 2009-03-25
US20140288028A1 (en) 2014-09-25
JP2012246323A (ja) 2012-12-13
ES2384116T3 (es) 2012-06-29
JP5662980B2 (ja) 2015-02-04
ATE549317T1 (de) 2012-03-15
RU2440986C2 (ru) 2012-01-27
NZ592533A (en) 2012-08-31
WO2007056517A3 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
AR106960A2 (es) SALES Y POLIMORFOS FARMACÉUTICOS DE UN INHIBIDOR DEL FACTOR Xa
Yusuf et al. Syntheses and anti-depressant activity of 5-amino-1, 3, 4-thiadiazole-2-thiol imines and thiobenzyl derivatives
GT200600420A (es) Sales novedosas de lisina de derivados de acido 4-((fenoxialquil)tio)-fenoxiacetico
NO20070295L (no) Nye CIS-imidazoliner
AR060174A1 (es) Un proceso para preparar derivados de tetrahidroquinolina
AR088372A1 (es) Solucion para administracion oral
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
PT1274698E (pt) Perciquinina, metodo para a sua producao e sua utilizacao como medicamento
UY31917A (es) Compuestos de pirido-pirimidina inhibidores de mtor, composiciones farmaceuticas que los comprenden, procesos para su preparación y su uso como medicamento.
AR069491A1 (es) Polimorfos de un inhibidor de c-met/ hgfr
MY148953A (en) Substituted biphenyl carboxylic acids and derivatives thereof
ATE465992T1 (de) Beta-kristalline form von perindopril-arginin- salz, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
IL192066A (en) Method for the production of ramipril
CN110913854A (zh) mitoketoscin：靶向癌细胞中酮代谢的基于线粒体的治疗剂
ATE529181T1 (de) Neuartiges dispersionsmittel und zusammensetzungen daraus
UA92733C2 (ru) Способ получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
Annedi et al. 3, 5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors
NO20054389L (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
TH92799B (th) เกลือทางเภสัชกรรมใหม่และพหุสัณฐานของตัวยับยั้งปัจจัย Xa
WO2006040644A3 (en) Processes for the preparation of substituted thiochroman derivatives
UY29684A1 (es) Derivados de piperidina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
GEP20094657B (en) New strontium salts of sulphonic acids, preparation method and pharmaceutical compositions containing them
TW200621691A (en) Chiral 3-halophthalic acid derivatives
HK1187922A (zh) 芳基磺醯胺鹽ccr3拮抗劑
AR031748A1 (es) Formulaciones liquidas acuosas

Legal Events

Date Code Title Description
FB Suspension of granting procedure